ENANTA PHARMACEUTICALS, INC Deferred Income Tax Expense (Benefit)
ENANTA PHARMACEUTICALS, INC (ENTA) reported Deferred Income Tax Expense (Benefit) of -$18.26 million for the 12-month period ending 2020-09-30, per its 10-K filed 2021-11-24.
Discontinued › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2021-11-24
- ENANTA PHARMACEUTICALS, INC deferred income tax expense (benefit) for the quarter ending 2014-09-30 was $17.00K.
- ENANTA PHARMACEUTICALS, INC deferred income tax expense (benefit) for fiscal 2020 was -$18.26M.
- ENANTA PHARMACEUTICALS, INC deferred income tax expense (benefit) for fiscal 2014 was -$15.21M.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|---|---|
| 2020-09-30 | -$18.26M 10-K · filed 2021-11-24 | ||
| 2014-09-30 | $17.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-12-11 | -$15.21M 10-K · filed 2014-12-11 | |
| 2014-06-30 | -$15.23M 10-Q · filed 2014-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |